Heart Failure

A multi-country study in Asia has revealed patients with both type 2 diabetes and heart failure face higher odds of structural CV abnormalities, a poorer quality of life and an increased risk of death.

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.

The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT. 

Biopharmaceutical company Renovacor, Inc., on August 14 announced it had raised $11 million in Series A financing to further develop its gene therapy-based treatments for CVD.

A study published in JAMA Network Open August 11 suggests that, despite the growing use of imaging modalities like computed tomography and MRI, echocardiography remains the most popular method for imaging patients with heart failure.

Newly diagnosed HF patients with concomitant mitral regurgitation can expect more admissions, longer hospital stays and pricier medical bills than HF patients without MR, according to an analysis published in the American Journal of Cardiology.

Swiss drugmaker Novartis on July 29 announced its combo sacubitril/valsartan drug Entresto “narrowly missed” its primary endpoint in the Phase III PARAGON-HF study, throwing into question the future of a blockbuster drug.

A study published July 17 in the Journal of the American College of Cardiology has revealed a strong link between cancer and takotsubo cardiomyopathy, or “broken heart syndrome.”

Methamphetamine abuse is on the rise among veterans with concomitant heart failure, according to a recent analysis published in the American Journal of Cardiology

Researchers in Italy are developing “smart,” photo-responsive materials they hope will replicate the mechanical properties of a human heart in an artificial format, Cosmos Magazine reported July 12.

The Center to Advance Palliative Care suggests steps cardiologists can take to ensure ongoing identification and management of remediable sources of suffering and distress in heart failure patients.

The combination heart failure drug sacubitril/valsartan is well-covered under Medicare Part D plans, according to a recent analysis, but patient access to the medication remains limited by steep out-of-pocket costs than can exceed $1,600 annually.